SCHEMBL12763489

SCHEMBL12763489

CCc1ccccc1-c1c[nH]c2ncc(-c3ccc4[nH]ccc4c3)cc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K11 Q16584 16/20 0.69
▸ DYRK1A Q13627 2/20 0.63
▸ DYRK2 Q92630 2/20 0.63
▸ DYRK1B Q9Y463 2/20 0.63
▸ CLK1 P49759 1/20 0.63
▸ CYP3A4 P08684 3/20 0.60
▸ CYP2D6 P10635 2/20 0.60
▸ LRRK2 Q5S007 3/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ CDK2 P24941 2/20 0.54
▸ CCNT1 O60563 1/20 0.54
▸ CCNA2 P20248 1/20 0.54
▸ CDK9 P50750 1/20 0.54
▸ SGK1 O00141 2/20 0.54
▸ IKBKB O14920 1/20 0.54
▸ AURKA O14965 1/20 0.54
▸ CHUK O15111 1/20 0.54
▸ PRKAB2 O43741 1/20 0.54
▸ ROCK2 O75116 1/20 0.54
▸ ABL1 P00519 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12763487 0.86 MAP3K11 (0.68) MAP3K11DYRK1ADYRK2DYRK1BCLK1
SCHEMBL12763559 0.83 MAP3K11 (0.76) MAP3K11DYRK1ADYRK2DYRK1BCLK1
SCHEMBL723789 0.83 MAP3K11 (1.00) MAP3K11DYRK1ADYRK2DYRK1BCLK1
SCHEMBL1516737 0.81 DYRK1A (0.66) DYRK1ADYRK2DYRK1BCLK1CDK2
SCHEMBL12762896 0.81 TNIK (0.54) CDK2CCNT1CCNA2CDK9SGK1
SCHEMBL721629 0.81 MAP3K11 (1.00) MAP3K11DYRK1ADYRK2DYRK1BCLK1
SCHEMBL12763494 0.81 MAP3K11 (0.72) MAP3K11DYRK1ADYRK2DYRK1BCLK1
SCHEMBL12763441 0.80 CCNT1 (0.60) CDK2CCNT1CCNA2CDK9SGK1
SCHEMBL12763473 0.79 MAP3K11 (0.67) MAP3K11DYRK1ADYRK2DYRK1BCLK1
SCHEMBL12836718 0.79 SGK1 (0.59) DYRK1ADYRK2DYRK1BCLK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906648-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2011-03-15 — — US disclosed
US-7906648-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2011-03-15 — — US disclosed
EP-2264033-A1 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS SGX Pharmaceuticals, Inc. (US) 2010-12-22 — — EP disclosed
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 — — US disclosed
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 — — US disclosed
US-20090306056-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-12-10 — — US disclosed
US-20090306056-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-12-10 — — US disclosed
US-7601839-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS INC. (US) 2009-10-13 — — US disclosed
US-7601839-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS INC. (US) 2009-10-13 — — US disclosed
US-7582637-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-09-01 — — US disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 — — WO disclosed
US-20080221119-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-09-11 — — US disclosed
US-20080221119-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-09-11 — — US disclosed
US-7361764-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 — — US disclosed
US-7361763-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 — — US disclosed
US-7361763-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 — — US disclosed
US-7361764-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 — — US disclosed
WO-2007106236-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-09-20 — — WO disclosed
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine SGX PHARMACEUTICALS, INC. (US) 2007-02-22 — — US disclosed
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine SGX PHARMACEUTICALS, INC. (US) 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306056-A1 PYRROLO-PYRIDINE KINASE MODULATORS MAP3K20, MAP4K2, MAP3K19 MAP3K11 19/4885DYRK1A 261/4885DYRK2 227/4885
US-20080221119-A1 PYRROLO-PYRIDINE KINASE MODULATORS MAP3K20, MAP4K2, MAP3K19 MAP3K11 19/4885DYRK1A 261/4885DYRK2 227/4885
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine MAP3K20, MAP4K2, MAP3K6 MAP3K11 21/4885DYRK1A 673/4885DYRK2 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback